Optimal management of recurrent prostate cancer in older patients

Drugs and Aging

Volumn 29, Issue 11, 2012, Pages 871-883

  Kessler, Elizabeth R ^a   Flaig, Thomas W ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; CABAZITAXEL; CABOZANTINIB; DENOSUMAB; DIETHYLSTILBESTROL; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; KETOCONAZOLE; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SAMARIUM 153; SIPULEUCEL T; STRONTIUM 89; ZOLEDRONIC ACID;

ADRENAL INSUFFICIENCY; ADVANCED CANCER; AGED; ASTHENIA; BONE DENSITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL DECISION MAKING; COMORBIDITY; DAILY LIFE ACTIVITY; DIARRHEA; DRUG DOSE REDUCTION; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FRAIL ELDERLY; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; JAW OSTEONECROSIS; LIFE EXPECTANCY; LIVER FUNCTION TEST; MALAISE; MALE; MASTALGIA; METABOLIC SYNDROME X; NUTRITIONAL STATUS; ORCHIECTOMY; OSTEOPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SIDE EFFECT; SOCIOECONOMICS; WEIGHT GAIN;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BONE DISEASES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84874624311     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0021-4     Document Type: Review

References (95)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Heinzer H, Steuber T. Prostate cancer in the elderly. Urol Oncol. 2009;27(6):668-72.
3. Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31(2):128-36. (Pubitemid 38481234)
4. National Center for Health Statistics. Health, United States, 2010: with special feature on death and dying. Hyattsville, MD: National Center for Health Statistics; 2011.
5. Marenco D, Marinello R, Berruti A, Gaspari F, Stasi MF, Rosato R, et al. Multidimensional geriatric assessment in treatment decision in elderly cancer patients: 6-year experience in an outpatient geriatric oncology service. Crit Rev Oncol Hematol. 2008;68(2):157-64.
6. Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol. 2011;29(27):3636-42.
7. Groome PA, Rohland SL, Siemens DR, Brundage MD, Heaton J, Mackillop WJ. Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates. Cancer. 2011;117(17):3943-52.
8. Froehner M, Koch R, Litz RJ, Oehlschlaeger S, Twelker L, Hakenberg OW, et al. Detailed analysis of Charlson comorbidity score as predictor of mortality after radical prostatectomy. Urology. 2008;72(6):1252-7.
9. Simone NL, Singh AK, Cowan JE, Soule BP, Carroll PR, Litwin MS. Pretreatment predictors of death from other causes in men with prostate cancer. J Urol. 2008;180(6):2447-51. (discussion 51-52).
10. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24(24):3973-8. (Pubitemid 46630746)
11. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171(4):1393-401. (Pubitemid 38365382)
12. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232-7. (Pubitemid 46606398)
13. Post PN, Kil PJ, Hendrikx AJ, Janssen-Heijnen ML, Crommelin MA, Coebergh JW. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int. 1999;84(6):652-6. (Pubitemid 29457182)
14. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92(8):613-21. (Pubitemid 30321303)
15. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010;106(4):462-9.
16. National Comprehensive Cancer Network. Senior adult oncology v.2.2012. http://www.nccn.org/professionals/physician-gls/pdf/senior.pdf. Accessed 25 Oct 2012.
17. Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241-52. (Pubitemid 41219694)
18. Terret C, Albrand G, Droz JP. Geriatric assessment in elderly patients with prostate cancer. Clin Prostate Cancer. 2004;2(4):236-40. (Pubitemid 38500694)
19. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494-502. (Pubitemid 34072534)
20. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(4 Suppl 2):18-24.
21. Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med. 1999;341(24):1837-8.
22. Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer. 2000;88(6):1454-63. (Pubitemid 30155185)
23. Fossa SD, Woehre H, Kurth KH, Hetherington J, Bakke H, Rustad DA, et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol. 1997;31(Suppl 3):3-8. (Pubitemid 27152013)
24. van Andel G, Kurth KH. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol. 2003;44(2):209-14. (Pubitemid 36917005)
25. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979-83. (Pubitemid 46630747)
26. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;26(33):5465-76.
27. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57(1):127-32. (Pubitemid 32065833)
28. Flaig TW, Glode LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother. 2008;9(16):2829-41.
29. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2001;86(2):724-31. (Pubitemid 32207487)
30. Bylow K, Mohile SG, Stadler WM, Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer. 2007;110(12):2604-13. (Pubitemid 350250329)
31. Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 2006;54(6):991-1001. (Pubitemid 43847040)
32. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol. 1999;17(7):2027-38. (Pubitemid 29318831)
33. Lundgren R. Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol. 1987;59(2):156-8. (Pubitemid 17018860)
34. Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol. 1991;146(2):377-81.
35. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132(7):566-77. (Pubitemid 30171897)
36. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997;80(9):1755-9. (Pubitemid 27475933)
37. Trump DL, Havlin KH, Messing EM, Cummings KB, Lange PH, Jordan VC. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol. 1989;7(8):1093-8. (Pubitemid 19196533)
38. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10(2):440-8. (Pubitemid 38173980)
39. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22(6):1025-33. (Pubitemid 41095034)
40. Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002;168(2):542-5. (Pubitemid 34793290)
41. Emtage LA, Trethowan C, Kelly K, Arkell D, Wallace DM, Hughes M, et al. A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study. Prog Clin Biol Res. 1989;303:47-52.
42. Smith PH, Suciu S, Robinson MR, Richards B, Bastable JR, Glashan RW, et al. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J Urol. 1986;136(3):619-23. (Pubitemid 16012494)
43. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology. 1998;52(2):257-60. (Pubitemid 28357829)
44. Clemons J, Glode LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol. 25 Jul 2011 [Epub ahead of print].
45. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756-64. (Pubitemid 26185452)
46. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506-13. (Pubitemid 29368252)
47. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12. (Pubitemid 39315317)
48. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20. (Pubitemid 39315318)
49. Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9):1547-52.
50. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):723-30.
51. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
52. Sanofi-Aventis. Cabazitaxel versus docetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA) (ClinicalTrials.gov Identifier NCT01308567). 2011. http://www.clinicaltrials. gov. Accessed 29 Nov 2011.
53. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15(15):4792-8.
54. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-54.
55. Rowan BG, Weigel NL, O'Malley BW. Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem. 2000;275(6):4475-83. (Pubitemid 30094692)
56. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem. 2004;279(8):7119-30. (Pubitemid 38248859)
57. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004;11(3):459-76. (Pubitemid 39331277)
58. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563-71.
59. Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol. 2003;84(5):555-62. (Pubitemid 36588809)
60. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28(9):1481-8.
61. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28(9):1496-501.
62. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
63. Janssen Research and Development, LLC. A phase 3 randomized, double-blind, placebo-controlled study of abiraterone acetate (CB7630) plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (ClinicalTrials.gov Identifier NCT00887198). 2011. http://www.clinicaltrials.gov. Accessed 30 Nov 2011.
64. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-90.
65. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437-46.
66. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97.
67. Medivation, Inc. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL) (ClinicalTrials.gov Identifier NCT01212991). 2011. http://www.clinicaltrials.gov. Accessed 25 Nov 2011.
68. Astellas Pharma Inc. A study of MDV3100 versus bicalutamide in castrate men with metastatic prostate cancer (ClinicalTrials.gov Identifier NCT01288911). 2011. http://www.clinicaltrials.gov. Accessed 25 Nov 2011.
69. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
70. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089-94. (Pubitemid 46638945)
71. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670-9.
72. Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res. 2011;17(12):3884-91.
73. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res. 2007;13(13):3776-82. (Pubitemid 47037581)
74. Dendreon. Sequencing of sipuleucel-T and ADT in men with non-metastatic prostate cancer (ClinicalTrials.gov Identifier: NCT01431391). 2011. http://www.clinicaltrials.gov. Accessed 25 Nov 2011.
75. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011;17(13):4558-67.
76. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer. 1995;63(2):231-7.
77. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006;4:1. (Pubitemid 43078809)
78. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007;178(4 Pt 1):1515-20. (Pubitemid 47368382)
79. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-105.
80. BN ImmunoTherapeutics. A trial of PROSTVAC +/- GM-CSF in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC) (Prospect) (ClinicalTrials.gov Identifier NCT01322490). 2011. http://www.clinicaltrials.gov. Accessed 30 Nov 2011.
81. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-82. (Pubitemid 38807610)
82. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-22.
83. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 15 Nov 2011 [Epub ahead of print].
84. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745-55.
85. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27(8):954-8.
86. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574-81. (Pubitemid 28175783)
87. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587-94. (Pubitemid 46995621)
88. Parker C, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki, A et al. Overall Survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol. 2012; 30(Suppl 5; Abstr 8).
89. Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290-6.
90. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol. 2010;73(1):68-91.
91. Sonpavde G. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;365(8):766-7. (author reply 7-8).
92. Agus DB, Stadler WM, Shevrin DH, Hart L, MacVicar GR, Hamid O, et al. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study (abstract). J Clin Oncol. 2011;29(15s):4531.
93. Millennium Pharmaceuticals, Inc. Study comparing orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. (ClinicalTrials.gov Identifier NCT01193244). 2011. http://www.clinicaltrials.gov. Accessed 25 Nov 2011.
94. Millennium Pharmaceuticals, Inc. Study comparing orteronel plus prednisone in patients with metastatic castration-resistant prostate cancer (ClinicalTrials.gov Identifier NCT01193257). 2011. http://www.clinicaltrials. gov. Accessed 25 Nov 2011.
95. Hussain M, Smith UN, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol. 2011;29(7 suppl):abst 4516. (47th Ann Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011).